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The C-terminal helix 9 motif in rat
cannabinoid receptor type 1 regulates
axonal trafficking and surface expression
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Kevin A Wilkinson, Jeremy M Henley*
School of Biochemistry, Centre for Synaptic Plasticity, University of Bristol, Bristol,
United Kingdom
Abstract Cannabinoid type one receptor (CB1R) is only stably surface expressed in axons,
where it downregulates neurotransmitter release. How this tightly regulated axonal surface polarity
is established and maintained is unclear. To address this question, we used time-resolved imaging
to determine the trafficking of CB1R from biosynthesis to mature polarised localisation in cultured
rat hippocampal neurons. We show that the secretory pathway delivery of CB1R is axonally biased
and that surface expressed CB1R is more stable in axons than in dendrites. This dual mechanism is
mediated by the CB1R C-terminus and involves the Helix 9 (H9) domain. Removal of the H9 domain
increases secretory pathway delivery to dendrites and decreases surface stability. Furthermore,
CB1RDH9 is more sensitive to agonist-induced internalisation and less efficient at downstream
signalling than CB1RWT. Together, these results shed new light on how polarity of CB1R is
mediated and indicate that the C-terminal H9 domain plays key roles in this process.
DOI: https://doi.org/10.7554/eLife.44252.001
Introduction
CB1R is one of the most abundant G-protein-coupled receptors (GPCRs) in the CNS and endocanna-
binoid signalling through CB1R is a neuromodulatory system that influences a wide range of brain
functions including pain, appetite, mood, and memory (Soltesz et al., 2015; Lu and Mackie, 2016).
Furthermore, CB1R function and dysfunction are implicated in multiple neurodegenerative disorders
(Basavarajappa et al., 2017). Thus, modulation of endocannabinoid pathways is of intense interest
as a potential therapeutic target (Reddy, 2017).
CB1R is present in both excitatory and inhibitory neurons, and also in astroglia, where it plays
important roles in synaptic plasticity and memory (Han et al., 2012; Robin et al., 2018; Busquets-
Garcia et al., 2018). In hippocampal neurons, ~80% of CB1R is present in intracellular vesicular clus-
ters in the soma and dendrites (Leterrier et al., 2006). Strikingly, however, CB1R is not stably sur-
face expressed on somatodendritic plasma membrane. Rather, it has a highly polarised axonal
surface expression (Irving et al., 2000; Coutts et al., 2001) where it acts to attenuate neurotrans-
mitter release (Katona, 2009) and modulate synaptic plasticity (Lu and Mackie, 2016).
How this near exclusive axonal surface expression of CB1R is established remains the subject of
debate. One suggestion is that high rates of endocytosis due to constitutive activity selectively
remove CB1Rs from the somatodendritic plasma membrane, resulting in an accumulation at the axo-
nal surface (Leterrier et al., 2006). These internalised somatodendritic CB1Rs may then be either
sorted for degradation or recycled to axons via a transcytotic sorting pathway (Simon et al., 2013).
Alternatively, newly synthesized CB1Rs may be constitutively targeted to lysosomes, but under
appropriate circumstances the CB1Rs destined for degradation are retrieved and rerouted to axons
(Rozenfeld and Devi, 2008; Rozenfeld, 2011).
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Surprisingly, a direct role for the 73-residue intracellular C-terminal domain of CB1R (ctCB1R) in
axonal/somatodendritic trafficking or polarised surface expression has not been identified. It has,
however, been reported that motifs within ctCB1R are required for receptor desensitization and
internalization (Hsieh et al., 1999; Jin et al., 1999) (reviewed by Mackie, 2008). Interestingly, there
are two putative amphipathic helical domains in ctCB1R (H8 and H9 [Ahn et al., 2009]). H8 has been
proposed to play a role in ER assembly and/or exit during biosynthesis (Ahn et al., 2010;
Stadel et al., 2011). The role of the 21-residue H9 motif is unknown, although analogous regions
have been reported to act as a Gaq-binding site in both squid rhodopsin (Murakami and Kouyama,
2008) and bradykinin receptors (Piserchio et al., 2005).
Here we systematically investigated how axonal surface polarity of CB1R arises by tracking newly-
synthesised CB1Rs through the secretory pathway to their surface destination. We demonstrate that
a population of CB1R is preferentially targeted to the axon through the biosynthetic pathway.
CB1Rs that reach the dendritic membrane are rapidly removed by endocytosis whereas CB1Rs sur-
face expressed on the axonal membrane have a longer residence time. We further show that the
putative helical domain H9 in ctCB1R plays a key role in CB1R surface expression and endocytosis in
hippocampal neurons. Taken together our data suggest that CB1R polarity is determined, at least in
part, by a novel determinant in the C-terminus of CB1R that contributes to targeted delivery to the
axonal compartment and the rapid removal of CB1Rs that reach the somatodendritic membrane.
eLife digest The brain contains around 100 billion neurons that are in constant communication
with one another. Each consists of a cell body, plus two components specialized for exchanging
information. These are the axon, which delivers information, and the dendrites, which receive it. This
exchange takes place at contact points between neurons called synapses. To send a message, a
neuron releases chemicals called neurotransmitters from its axon terminals into the synapse. The
neurotransmitters cross the synapse and bind to receptor proteins on the dendrites of another
neuron. In doing so, they pass on the message.
Cannabinoid type 1 receptors (CB1Rs) help control the flow of information at synapses. They do
this by binding neurotransmitters called endocannabinoids, which are unusual among
neurotransmitters. Rather than sending messages from axons to dendrites, endocannabinoids send
them in the opposite direction. Thus, it is dendrites that release endocannabinoids, which then bind
to CB1Rs in axon terminals. This backwards, or ’retrograde’, signalling dampens the release of other
neurotransmitters. This slows down brain activity, and gives rise to the ’mellow’ sensation that
recreational cannabis users often describe.
Like most other proteins, CB1Rs are built inside the cell body. So, how do these receptors end up
in the axon terminals where they are needed? Are they initially sent to both axons and dendrites,
with the CB1Rs that travel to dendrites being rerouted back to axons? Or do the receptors travel
directly to the axon itself? Fletcher-Jones et al. tracked newly made CB1Rs in rat neurons growing in
a dish. The results revealed that the receptors go directly to the axon, before moving on to the axon
terminals. A specific region of the CB1R protein is crucial for sending the receptors to the axon, and
for ensuring that they do not get diverted to the dendrite surface. This region stabilizes CB1Rs at
the axon surface, and helps to make the receptors available to bind endocannabinoids.
CB1Rs also respond to medical marijuana, a topic that continues to generate interest as well as
controversy. Activating CB1Rs could help treat a wide range of diseases, such as chronic pain,
epilepsy and multiple sclerosis. Future studies should build on our understanding of CB1Rs to
explore and optimize new therapeutic approaches.
DOI: https://doi.org/10.7554/eLife.44252.002
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Results
Preferential delivery of newly synthesized CB1Rs to, and retention at,
the axonal membrane establishes surface polarisation
To investigate how CB1R surface polarity is established we used the retention using selective hooks
(RUSH) system (Boncompain et al., 2012) and antibody feeding techniques to examine its secretory
pathway trafficking and surface expression (Figure 1). We used CB1R tagged at the N-terminus with
streptavidin binding peptide (SBP) and EGFP (SBP-EGFP-CB1R). When co-expressed with a Strepta-
vidin-KDEL ‘hook’ that localises to the lumen of the Endoplasmic Reticulum (ER), SBP-EGFP-CB1R is
anchored at the ER membrane. The retained SBP-EGFP-CB1R can then be synchronously released
by addition of biotin and its trafficking through the secretory pathway and surface expression in
both axons and dendrites can be monitored (Evans et al., 2017).
CB1R is directly trafficked to the axon through the secretory pathway
We first examined the synchronous trafficking of total SBP-EGFP-CB1R in the somatodendritic and
axonal compartments of primary hippocampal neurons (Figure 2A–C). Prior to biotin-mediated
release, SBP-EGFP-CB1R was retained in the ER in the soma and dendrites but was absent from the
axonal compartment and was not present at the cell surface (0 min; Figure 2A). After addition of
biotin, SBP-EGFP-CB1R moved through the secretory pathway and entered the proximal segment of
the axonal compartment at 25 min and continued to accumulate until 45 min when it reached its
peak, which was comparable to an unretained control (O/N) (Figure 2B–C). These data suggest that
once released from the ER, CB1R is immediately trafficked towards the axonal compartment, and
passes through the axon initial segment (AIS), which constitutes an exclusion and diffusion barrier to
separate the axonal from the somatodendritic compartments, via the intracellular secretory pathway.
Figure 1. Schematic of RUSH assay and antibody feeding protocol. (1) Before the addition of biotin, SBP-EGFP-
CB1R is retained in the ER by a streptavidin-KDEL hook (0 min). (2) Addition of biotin (orange triangles) releases
the receptor and it begins to accumulate at the surface. (3) Antibody feeding with anti-GFP antibodies during
biotin-mediated release labels newly delivered, surface expressed SBP-EGFP-CB1R. (4) A proportion of receptors
internalise, still bound to primary antibody. (5) Cells are cooled to 4˚C to prevent further internalisation. Live
secondary antibody incubation labels retained surface receptors (indicated by magenta star). (6) After fixation and
permeabilization, incubation with a different secondary antibody labels all receptors delivered to the surface
during the time course of the experiment (red star = surface + endocytosed).
DOI: https://doi.org/10.7554/eLife.44252.003
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Figure 2. Newly synthesized CB1Rs are preferentially delivered to, and retained at, the axonal membrane to establish surface polarisation. The
trafficking of SBP-EGFP-CB1R following release with biotin was monitored after 0 (no biotin), 15, 25, 30, 35, 40, 45, 60, 90 min, and overnight (O/N; non-
retained control) in DIV 13 hippocampal neurons. Upper panels for each condition show whole cell field of view and lower panels are enlargements of
axonal (a) and dendritic (d) ROIs. Green = total; red = surface + endocytosed; magenta = surface; blue = axon marker (Ankyrin-G). In all images the
Figure 2 continued on next page
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De novo CB1R is more rapidly surface expressed in axons than in dendrites
Having established that SBP-EGFP-CB1R released from the ER traffics directly to axons, we next
investigated where and when the newly synthesised SBP-EGFP-CB1R first reaches the plasma mem-
brane. We determined how much SBP-EGFP-CB1R was surface expressed during a given time
period using an antibody feeding assay (Evans et al., 2017) (Figure 1). Antibody feeding was per-
formed concurrent with the addition of biotin to release ER-retained SBP-EGFP-CB1R. This protocol
labels both surface expressed CB1Rs and those that have been surface expressed and subsequently
endocytosed (Figure 1; Figure 2D–G; surface + endocytosed), giving a measure of total amount of
surface expression irrespective of internalisation. SBP-EGFP-CB1R was surface expressed in the
proximal segment of axons 40 min after release from the ER, whereas in dendrites, CB1R was not
surface expressed until 60 min after release (Figure 2E). Moreover, significantly more SBP-EGFP-
CB1R reached the surface of axons than the surface of dendrites 45, 60, and 90 min after release
from the ER (Figure 2E). These data demonstrate that the secretory pathway delivers a greater
amount of CB1R more rapidly to the axonal membrane than to the dendritic membrane.
De novo CB1R is retained longer at the surface of axons than of dendrites
It has been suggested CB1R polarity is maintained by differential rates of endocytosis in the somato-
dendritic and axonal compartments (Leterrier et al., 2006; McDonald et al., 2007a). To test this,
we also stained for surface SBP-EGFP-CB1R and compared the amount of surface expressed SBP-
EGFP-CB1R to the amount of surface + endocytosed SBP-EGFP-CB1R in axons (Figure 2D,F) and
dendrites (Figure 2D,G). In the proximal segment of axons, the normalised surface and
surface + endocytosed curves were identical, suggesting that most surface expressed SBP-EGFP-
CB1R is stable and retained at the axonal membrane (Figure 2D,F). This may be due either to mini-
mal endocytosis or to the efficient recycling of endocytosed receptors. In stark contrast, however, in
Figure 2 continued
scale bar = 20 mm. (A) Representative image of a hippocampal neuron expressing the RUSH construct SBP-EGFP-CB1R without biotin (0 min). SBP-
EGFP-CB1R is anchored in the ER of the somatodendritic compartment and is not detected in the proximal 50 mm of axons or on the surface of
dendrites. Merge: green = total; blue = Ankyrin G; red = surface + endocytosed; magenta = surface. (B) Representative confocal images of total SBP-
EGFP-CB1R expressed in DIV 13 hippocampal neurons 25 min and 45 min after biotin release from the ER showing that SBP-EGFP-CB1R has entered
the proximal axonal compartment (initial 50 mm). Merge: green = total; blue = Ankyrin G. (C) Quantification of data represented in (A and B). SBP-
EGFP-CB1R was initially absent from the axon but entered after 25 min and continued to accumulate until it plateaued after 45 min to a level
comparable to a non-retained control (O/N). One-way ANOVA with Tukey’s post hoc test. N = three to six independent experiments, n = 19–45
neurons per condition. 0 min vs. 25 min: mean ± SEM, 0.307 ± 0.0173 vs. 0.729 ± 0.0772; N = 6, n = 45 vs. N = 3, n = 19; **p = 0.0018. 30 min vs. ON:
mean ± SEM, 1.03 ± 0.0597 vs. 1.2 ± 0.0632; N = 4, n = 32 vs. N = 4, n = 24, nsp = 0.8186. (D) Representative confocal images of total and surface
expressed SBP-EGFP-CB1R in DIV 13 hippocampal neurons 40 min and 90 min after biotin-mediated release showing that SBP-EGFP-CB1R is
preferentially delivered to, and retained at, the axonal surface. Merge: surface to total seen as white; endocytosed to total seen as yellow. (E)
Quantification of data represented in (D). SBP-EGFP-CB1R reached the proximal surface of the axon 40 min after release and the surface of dendrites
60 min after release. Furthermore, significantly more SBP-EGFP-CB1R reached the axonal versus dendritic surface at 45, 60, and 90 min. 45 min, Axons
vs. Dendrites: mean ± SEM, 0.723 ± 0.077 vs. 0.319 ± 0.035; N = 3, n = 20 vs. N = 3, n = 20; **p = 0.0054. 60 min, Axons vs. Dendrites: mean ± SEM,
1.00 ± 0.093 vs. 0.452 ± 0.023; N = 6, n = 46 vs. N = 6, n = 46; ****p < 0.0001. 90 min, Axons vs. Dendrites: mean ± SEM, 1.511 ± 0.129 vs. 0.566 ± 0.054;
N = 4, n = 26 vs. N = 4, n = 26; ****p < 0.0001. (F) Quantification of data represented in (D). Comparison between surface + endocytosed (red; see E)
and surface (magenta) curves show that SBP-EGFP-CB1R was retained on the surface of axons. (For all p > 0.9999). (G) Quantification of data
represented in (D). Comparison between surface + endocytosed (pale red; see (E) and surface (pale magenta) curves show that SBP-EGFP-CB1R was
internalised from the surface of dendrites. 90 min, SE vs. S: mean ± SEM, 0.766 ± 0.054 vs. 0.408 ± 0.038; N = 4, n = 26 vs. N = 4, n = 26; **p = 0.0046.
Statistical analyses in (E-G); Two-way ANOVA with Tukey’s post hoc test (all analysed and corrected for multiple comparisons together). Three to six
independent experiments, n = 19–45 neurons per condition. (H) Distribution of total CB1R along the first 100 mm of the axon indicates that CB1R is
trafficked within the axon. By 30 min after release from the ER, and before CB1R reaches the surface, CB1R is present at least 100 mm away from the
soma at levels comparable to an unretained control (O/N). The blue shaded portion indicates the location of the AIS (defined by Ankyrin-G
immunostaining). Two-way ANOVA with Sidak’s post hoc test. Four to six independent experiments, n = 12–18. 90–100 mm, 0 vs. 30 min: mean ± SEM,
0.163 ± 0.014 vs. 0.452 ± 0.045; N = 6, n = 12 vs. N = 4, n = 18; *p = 0.0243. 90–100 mm, 30 min vs. O/N: mean ± SEM, 0.452 ± 0.045 vs. 0.511 ± 0.066;
N = 4, n = 18 vs. N = 4, n = 15; nsp = 0.905. (I) Distribution of surface expressed CB1R along the first 100 mm of the axon shows an accumulation of
CB1R at the distal region of the AIS 90 min after release from the ER. This accumulation in the AIS is reduced in the O/N unretained control consistent
with lateral diffusion within the membrane. Two-way ANOVA with Sidak’s post hoc test. Four to six independent experiments, n = 12–18. 0–50 mm, 90
min vs. O/N: All points p  0.0285. 50–100 mm, 90 min vs. O/N: All points p  0.0878.
DOI: https://doi.org/10.7554/eLife.44252.004
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Figure 3. The C-terminal domain of CB1R, especially the Helix 9 motif, plays a role in axonal surface polarisation. (A) Amino acid sequence of the
C-terminus of rat CB1R highlighting helical motifs (Helix 8 and Helix 9) predicted from NMR spectroscopy and computational modelling. The proposed
interaction domains of CRIP1a and SGIP1, and the palmitoylated cysteine residue involved in membrane association and G-protein coupling, are also
indicated. A potentially post-translationally modified cysteine in H9 is highlighted. (B) Schematic of the CD4-ctCB1R chimeric proteins used. (C)
Representative confocal images of hippocampal neurons showing the distribution of expressed CD4 (left), CD4-ctCB1RWT (middle), or CD4-ctCB1RDH9
(right). Upper panels for each condition show a whole cell field of view and lower panels are enlargements of axonal (a) and dendritic (d) ROIs.
Green = total; magenta = surface; blue = dendrite marker (MAP2). Merge: surface to total seen as white. Scale bar = 20 mm. (D) Quantification of data
represented in (C) presented as the surface polarity index (A/D ratio). CD4-ctCB1RWT strongly favoured the axonal compartment compared to CD4
alone. CD4-ctCB1RDH9 favoured the axonal compartment significantly less than CD4-ctCB1RWT. One-way ANOVA with Tukey’s post hoc test. N = three
independent experiments; n = 28–33 neurons per condition. CD4 vs. WT: mean ± SEM, 0.834 ± 0.0255 vs. 1.52 ± 0.0696; N = 3, n = 30 vs. N = 3, n = 33;
****p < 0.0001. CD4 vs. DH9: mean ± SEM, 0.834 ± 0.0255 vs. 1.09 ± 0.0562; N = 3, n = 30 vs. N = 3, n = 28; **p = 0.0050. WT vs. DH9: mean ± SEM,
1.52 ± 0.0696 vs. 1.09 ± 0.0562; N = 3, n = 33 vs. N = 3, n = 28; ****p < 0.0001.
DOI: https://doi.org/10.7554/eLife.44252.005
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dendrites there is significantly less surface than surface + endocytosed SBP-EGFP-CB1R 90 min after
addition of biotin, indicating that surface expressed CB1R is more rapidly endocytosed from and/or
not recycled back to the dendritic membrane (Figure 2G).
CB1R is trafficked to more distal parts of the axon via intracellular
mechanisms
Analysis of CB1R total fluorescence along the axon indicates that by 30 min after release from the
ER, and before CB1R appears on the surface, intracellular CB1R has progressed through the AIS and
is already present at least 100 mm along the axon at levels similar to the unretained control (O/N;
Figure 2H,I). These data indicate that CB1R-containing secretory vesicles can rapidly travel to more
distal areas of the axon. Furthermore, surface CB1Rs delivered from the secretory pathway accumu-
late at the final portion of the AIS, before then progressing further along the axon (Figure 2I). Inter-
estingly, 100 mm along the axon CB1R levels reach a steady state 90 min after release, at levels
similar to when receptors are released overnight. However, following overnight release fewer recep-
tors remain in the most proximal region of the axon. These results suggest that additional mecha-
nisms contribute to the delivery of CB1R receptors the distal axon and presynaptic boutons. This
process occurs over a time-course of several hours and could involve lateral surface diffusion and
trapping analogous to the accumulation of AMPARs at the postsynaptic membrane (Borgdorff and
Choquet, 2002).
A two-part model of CB1R polarity
Our results using RUSH time-resolved analysis show that CB1R surface polarity is initially established
and maintained by two distinct but complementary mechanisms. Firstly, we show the novel finding
that the secretory pathway preferentially delivers CB1R to the axonal surface, with significantly less
going to the dendritic surface. Secondly, by distinguishing between surface and
surface + endocytosed receptors, our antibody feeding experiments show that newly delivered
CB1R is preferentially retained/stabilised at the axonal membrane and internalised from the den-
dritic membrane. Previous literature proposes that this differential internalisation is due to the pres-
ence of agonist in the dendritic membrane and absence of agonist on axonal membrane
(Leterrier et al., 2006; Ladarre et al., 2014), although a potential role for constitutive internalisation
distinct to agonist-induced internalisation has also been proposed (McDonald et al., 2007a). Taken
together, we propose that preferential delivery to the proximal segment of the axon and less rapid
internalisation of axonally surface expressed CB1Rs are major contributors to the axonal surface
polarisation of CB1R in hippocampal neurons.
H9 contributes to axonal surface polarisation
The intracellular ctCB1R is implicated in desensitization and internalization (reviewed in
Mackie, 2008; Stadel et al., 2011) and structural motifs and potential interaction partners have
been identified (Figure 3A; Stadel et al., 2011). However, the role of this region in determining axo-
nal polarity has not been investigated and the function of the H9 structural motif is unknown. We
therefore wondered whether ctCB1R, and H9 in particular, contribute to CB1R surface polarisation.
To test the role of the C-terminal domain we initially used CD4, a single-pass membrane protein
that has no intrinsic localisation signals and is normally surface expressed in a non-polarised manner
(Garrido, 2001; Fache et al., 2004). We expressed chimeras of CD4 alone or CD4 fused to either
ctCB1RWT or a ctCB1R lacking the H9 domain (ctCB1RDH9; Figure 3B) in hippocampal neurons and
examined surface expression by immunostaining (Figure 3C).
Analysis of the axon to dendrite ratio of surface expression (the surface polarity index) revealed
that CD4-ctCB1RWT was markedly more axonally polarised than CD4 alone, indicating that ctCB1R
may play a role in polarisation despite its lack of defined canonical localisation signals. Moreover,
although still significantly axonally polarised, the degree of polarisation was significantly lower for
CD4-ctCB1RDH9, suggesting that H9 may also contribute to this process (Figure 3D).
We next analysed constitutive endocytosis of CD4-ctCB1RWT and CD4-ctCB1RDH9 (Figure 4A,B).
H9 does not determine surface polarity by driving differential constitutive endocytosis from either
the dendritic or axonal membrane since there was no difference between the internalisation of CD4-
ctCB1RWT or CD4-ctCB1RDH9. Interestingly, both CD4-ctCB1RWT and CD4-ctCB1RDH9 were
Fletcher-Jones et al. eLife 2019;8:e44252. DOI: https://doi.org/10.7554/eLife.44252 7 of 26
Research article Neuroscience
Figure 4. The C-terminal domain of CB1R plays a role in internalisation in dendrites independent of H9. (A)
Representative confocal images of DIV 14 primary hippocampal neurons expressing CD4DCT (left), CD4-ctCB1RWT
(middle), or CD4-ctCB1RDH9 (right). Neurons were subjected to 2 hr of antibody feeding followed by stripping of
surface antibody to reveal the endocytosed pool of receptors. Upper panels for each condition show a whole cell
field of view and lower panels are enlargements of axonal (a) and dendritic (d) ROIs. Green = total;
red = endocytosed; blue = dendritic marker (MAP2). Merge: endocytosed to total seen as yellow. Scale bar = 20
mm. (B) Quantification of data presented in (A). Both CD4-ctCB1RWT and CD4-ctCB1RDH9 were significantly more
internalised in dendrites, but not in axons, than CD4 alone. Three independent experiments; n = 24–26 neurons
per condition. Two way ANOVA with Sidak’s post hoc test. Axons, CD4 vs. WT vs. DH9: mean ± SEM, 1.00 ± 0.040
vs. 1.065 ± 0.039 vs. 1.148 ± 0.048; N = 3, n = 24 vs. N = 3, n = 26 vs. N = 3, n = 24; nsp  0.3514. Dendrites, CD4
vs. WT: mean ± SEM, 1.042 ± 0.038 vs. 1.250 ± 0.051; N = 3, n = 24 vs. N = 3, n = 26; *p = 0.0279. Dendrites, CD4
vs. DH9: mean ± SEM, 1.042 ± 0.038 vs. 1.355 ± 0.060; N = 3, n = 24 vs. N = 3, n = 24; *p < 0.0001. Dendrites, WT
vs. DH9: mean ± SEM, 1.250 ± 0.051 vs. 1.355 ± 0.060; N = 3, n = 26 vs. N = 3, n = 24; nsp = 0.8275.
DOI: https://doi.org/10.7554/eLife.44252.006
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significantly more internalised than CD4 alone in dendrites, but not in axons (Figure 4A,B). These
results suggest that a domain other than H9 promotes constitutive, but reportedly not activity-
dependent (McDonald et al., 2007a), internalisation in dendrites. Importantly, however, because
this increase in internalisation in identical between CD4-ctCB1RWT and ctCB1RDH9, this endocytic
mechanism does not account for the failure of CD4-ctCB1RDH9 to polarise to the level of CD4-
ctCB1RWT.
H9 restricts delivery of CB1R to the dendritic membrane
To further explore the possibility that H9 is involved in the axonal surface polarity of CB1R, we used
RUSH to compare the forward trafficking of SBP-EGFP-CB1RWT and SBP-EGFP-CB1RDH9. We
labelled all the CB1R that had been surface expressed (surface + endocytosed) 0, 30, 60, and 90 min
after biotin-mediated release from the ER. Representative neuronal images at 90 min after biotin-
mediated release are shown in Figure 5A.
Interestingly, significantly more SBP-EGFP-CB1RDH9 than SBP-EGFP-CB1RWT reached the surface
of dendrites during the time course of our experiments (Figure 5B), whereas trafficking to axons
was similar for both SBP-EGFP-CB1RWT and SBP-EGFP-CB1RDH9 (Figure 5C). These altered proper-
ties resulted in a significant difference in the surface + endocytosed polarity index after 90 min
(Figure 5D) and are consistent with a role for H9 in restricting delivery of CB1R to the dendritic
membrane.
H9 plays a role in the surface retention of CB1R
Surprisingly, in contrast to the total amount of CB1R that had been surface expressed during the
time course (surface + endocytosed; Figure 5D), the polarity of the amount of CB1R on the cell sur-
face 90 min after biotin-mediated release was identical for SBP-EGFP-CB1RWT and SBP-EGFP-
CB1RDH9 (surface; Figure 5E). Closer analysis revealed identical levels of axonal surface expression
of both SBP-EGFP-CB1RWT and SBP-EGFP-CB1RDH960 min after release from the ER. However, at 90
min there is significantly less surface expression of DH9 mutant (Figure 5F) suggesting that, although
similar amounts of SBP-EGFP-CB1RWT and SBP-EGFP-CB1RDH9 reach the surface, surface expression
of SBP-EGFP-CB1RDH9 is less stable than that of the wild-type. Furthermore, in dendrites, the
increased delivery and surface trafficking of the DH9 mutant is counteracted by the fact that less is
retained at the surface 60 min after ER release (Figure 5G). Taken together these results suggest
that, separate from its role in restricting delivery to the dendritic membrane, H9 also plays a role in
membrane stability and retention at both axons and dendrites.
H9 stabilises CB1R at the surface
To investigate the role of H9 in membrane stability, we next compared surface expression
(Figure 6A) and endocytosis (Figure 6B) of EGFP-CB1RWT and EGFP-CB1RDH9 in axons and den-
drites at steady-state. EGFP-CB1RDH9 displayed lower levels of surface expression (Figure 6C), as
well as increased endocytosis (Figure 6D) in both axons and dendrites compared to EGFP-CB1RWT,
suggesting H9 plays a role in stabilising CB1R at the surface of both axons and dendrites. Moreover,
similar to our findings using RUSH, there was no difference in surface polarity between EGFP-
CB1RWT and EGFP-CB1RDH9 (Figure 6E). These results suggest that, while H9 plays a role in CB1R
surface expression and endocytosis, its potential to mediate surface polarity is masked in the full-
length receptor.
CB1RDH9 is less efficient at activating downstream signalling pathways
and more susceptible to agonist-induced internalisation
Because CB1R surface expression and polarisation has been linked to its activity (Leterrier et al.,
2006; Ladarre et al., 2014), we investigated if deleting H9 affects CB1R downstream signalling
pathways. Measuring the signalling efficiency of EGFP-CB1RDH9 in neurons would require the com-
plete removal of endogenous CB1R so we expressed EGFP-CB1RWT or EGFP-CB1RDH9 in HEK293T
cells, which do not express endogenous CB1R (Atwood et al., 2011) and are routinely used to mea-
sure activation of the ERK pathway. Cells were treated with vehicle (EtOH) or stimulated with the
selective CB1R agonist ACEA (arachidonyl-2’-chloroethylamide) (Hillard et al., 1999) and blotted for
ERK1/2 phosphorylation as a measure of signalling downstream of CB1R (Daigle et al., 2008). There
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Figure 5. H9 both restricts delivery of CB1R to the dendritic membrane and plays a role in surface retention of CB1R. The trafficking of RUSH SBP-
EGFP-CB1R following release with biotin was monitored after 0 (no biotin), 30, 60, and 90 min in DIV 13 hippocampal neurons. (A) Representative
confocal images of hippocampal neurons expressing SBP-EGFP-CB1RWT or SBP-EGFP-CB1RDH9 90 min after release with biotin. Upper panels for each
condition show whole cell field of view and lower panels are enlargements of axonal (a) and dendritic (d) ROIs. Green = total;
red = surface + endocytosed; magenta = surface; blue = axon marker (Ankyrin-G). Merge: surface to total seen as white; endocytosed to total seen as
yellow. Scale bar = 20 mm. (B) Quantification of data represented in (A). Time-resolved analysis of surface + endocytosed receptors shows significantly
more SBP-EGFP-CB1RDH9 reaches the surface of dendrites than SBP-EGFP-CB1RWT, indicating that H9 may play a role in restricting delivery to the
dendritic surface. Two-way ANOVA with Sidak’s post hoc test. Three to seven independent experiments, n = 26–63 neurons per condition. 60 min, WT
vs. DH9: mean ± SEM, 0.497 ± 0.022 vs. 0.711 ± 0.036; N = 8, n = 63 vs. N = 8, n = 48; ****p < 0.0001. 90 min, WT vs. DH9: mean ± SEM, 0.766 ± 0.054
vs. 1.08 ± 0.066; N = 4, n = 26 vs. N = 4, n = 31; ****p < 0.0001. C) Quantification of data represented in (A). Time-resolved analysis of
surface + endocytosed receptors shows no difference between SBP-EGFP-CB1RWT and SBP-EGFP-CB1DH9 in reaching the surface of the axon. Two-way
ANOVA with Sidak’s post hoc test. N = three to seven independent experiments, n = 26–63 neurons per condition. 0, 30, 60, 90 min, WT vs. DH9:
p > 0.2459. (D) Quantification of data represented in (A). Analysis of surface + endocytosed polarity demonstrates a defect in polarised delivery of SBP-
EGFP-CB1RDH9 compared to SBP-EGFP-CB1RWT. Unpaired t-test. N = four independent experiments, n = 26–31 neurons per condition. WT vs. DH9:
mean ± SEM, 2.03 ± 0.136 vs. 1.46 ± 0.13; N = 4, n = 26 vs. N = 4, n = 31; **p = 0.0038. (E) Quantification of data represented in (A). Analysis of surface
polarity revealed no difference between SBP-EGFP-CB1RWT and SBP-EGFP-CB1DH9. Unpaired t-test. N = four independent experiments, n = 26–31
neurons per condition. WT vs. DH9: mean ± SEM, 3.935 ± 0.329 vs. 4.075 ± 0.361; N = 4, n = 26 vs. N = 4, n = 31; nsp = 0.7797. (F) Quantification of data
represented in (A). Time-resolved analysis of surface receptors shows significantly less SBP-EGFP-CB1DH9 than SBP-EGFP-CB1RWT on the surface of
axons 90 min after release, most likely due to increased endocytosis of the DH9 mutant. Two-way ANOVA with Sidak’s post hoc test. N = three to eight
independent experiments, n = 26–63 neurons per condition. 90, WT vs. DH9: mean ± SEM, 1.498 ± 0.144 vs. 1.154 ± 0.123; N = 4, n = 26 vs. N = 4,
n = 31; **p = 0.0066. (G) Quantification of data represented in (A). Time-resolved analysis of surface receptors shows significantly less SBP-EGFP-
CB1DH9 than SBP-EGFP-CB1RWT on the surface of dendrites 60 and 90 min after release, most likely due to increased endocytosis. Two-way ANOVA
with Sidak’s post hoc test. N = three to eight independent experiments, n = 26–63 neurons per condition. 60, WT vs. DH9: mean ± SEM, 0.262 ± 0.013
vs. 0.21 ± 0.018; N = 8, n = 63 vs. N = 8, n = 48; *p = 0.0232. 90, WT vs. DH9: mean ± SEM, 0.408 ± 0.038 vs. 0.312 ± 0.030; N = 4, n = 26 vs. N = 4,
n = 31; **p = 0.0011.
DOI: https://doi.org/10.7554/eLife.44252.007
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was no significant difference in ERK1/2 phosphorylation in cells expressing EGFP-CB1RWT or EGFP-
CB1RDH9 under basal conditions in the absence of ACEA. However, upon ACEA stimulation, the level
of ERK1/2 activation was significantly reduced in EGFP-CB1RDH9-transfected cells compared to
EGFP-CB1RWT-transfected cells expressing equivalent amounts of receptor (Figure 7A–C). Because
the DH9 mutant is more internalised than the wild-type in neurons, we examined whether the defi-
ciency in ERK1/2 phosphorylation was due to a similarly reduced surface expression in HEK283T
cells. However, EGFP-CB1RWT and EGFP-CB1RDH9 were surface expressed at equivalent levels in
HEK293T cells, as determined by surface biotinylation experiments (Figure 7D–E), suggesting the
DH9 mutant is deficient in its ability to activate downstream signalling pathways.
We next monitored ACEA-induced internalisation of EGFP-CB1RWT and EGFP-CB1RDH9 in axons
of hippocampal neurons (Figure 7F). ACEA-induced internalisation of EGFP-CB1RDH9 was signifi-
cantly greater than that observed for EGFP-CB1RWT (Figure 7F,G). Taken together, these data indi-
cate that CB1RDH9 is less stable at the axonal surface under basal conditions and that it is more
susceptible to agonist-induced internalisation.
The role of H9 in polarity is revealed in the presence of inverse agonist
Our data thus far indicate that ctCB1R, and the H9 domain in particular, can mediate surface polarity
of a CD4 chimera (Figure 3), and promote polarised surface delivery of CB1R (Figure 5). In contrast,
deletion of H9 has no effect on CB1R surface polarity at steady-state (Figure 6). However, deletion
of H9 does have a striking effect on the surface stability of CB1R with CB1RDH9 being less surface
expressed in both axons and dendrites and displaying increased endocytosis (Figures 4 and 6). Fur-
thermore, CB1R DH9 is more responsive to agonist-induced internalisation (Figure 7).
We therefore wondered whether the difference between the CD4 chimeras and the full-length
receptor and between surface + endocytosed and surface polarity may be attributable to the agonist
binding capability of the full-length receptor. To test this we used the CB1R-specific inverse agonist
AM281 to prevent the receptor entering an active conformation and which has previously been
shown to increase somatodendritic surface expression similar to treatment with an endocytosis inhib-
itor (Leterrier et al., 2006). We reasoned that AM281 might reveal a difference in surface polarity
between EGFP-CB1RWT and EGFP-CB1RDH9, like that observed with the CD4 chimeras and in
surface + endocytosed polarity.
In hippocampal neurons treated with the DMSO control both EGFP-CB1RWT and EGFP-CB1RDH9
displayed similar levels of surface polarity (Figure 8B). In the presence of AM281, however, EGFP-
CB1RDH9 had significantly reduced surface polarity compared EGFP-CB1RWT (Figure 8B) due to a
significantly increased amount of dendritic surface expression (Figure 8C).
These results indicate that in the absence of constitutive activity of the receptor, H9 plays a role
in mediating CB1R surface polarity. Furthermore, these data suggest that the increased internalisa-
tion observed in dendrites with H9 deletion may be mediated by the presence of endogenous ago-
nist and reaffirm the importance of the neuronal milieu on CB1R trafficking.
Discussion
Consistent with previous reports (Leterrier et al., 2006; Simon et al., 2013; Rozenfeld and Devi,
2008; McDonald et al., 2007b) we observed highly axonally polarised surface expression of CB1R.
As illustrated in schematic form in Figure 9, our data indicate that two distinct, but complementary,
mechanisms contribute to this polarisation of CB1Rs. 1) Using time-resolved RUSH assays we demon-
strate that more de novo CB1R is delivered to the axon and that it is more rapidly surface expressed
than in dendrites. 2) Once at the axonal membrane the newly delivered CB1R is more stably retained
whereas in dendritic membrane CB1R surface expression is transient and it is rapidly internalised. It
should be noted, however, that our data do not exclude additional possibilities, including that CB1R
internalised in the somatodendritic compartment can be rerouted to the axon via the transcytosis
pathway, thus further facilitating axonal polarity (Simon et al., 2013). Furthermore, since CD4-
ctCB1RWT and CD4-ctCB1RDH9 chimeras cannot bind agonist, our results are consistent with ctCB1R
contributing to constitutive polarisation via a mechanism distinct from the proposed continuous acti-
vation of CB1R by the presence of the endogenous agonist 2-Arachidonoylglycerol (2-AG) in the
dendritic membrane (Ladarre et al., 2014). Thus, we conclude that ctCB1R contributes to the consti-
tutive preferential delivery of CB1R to the axonal membrane.
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Figure 6. H9 stabilises CB1R at the axonal surface. (A) Representative confocal images of surface stained DIV 14
hippocampal neurons expressing EGFP-CB1RWT or EGFP-CB1RDH9. Green = total; magenta = surface; blue = axon
marker (Ankyrin-G). Merge: surface to total seen as white. (B) Representative confocal images of DIV 14 primary
hippocampal neurons expressing EGFP-CB1RWT or EGFP-CB1RDH9. Neurons were subjected to 2 hr of antibody
feeding followed by stripping off of surface antibody to reveal the endocytosed pool of receptors. Green = total;
red = endocytosed; blue = axon marker (Ankyrin-G). Merge: endocytosed to total seen as yellow. (C)
Quantification of data shown in (A). Surface expression of EGFP-CB1RDH9 in both axons and dendrites was
significantly reduced compared to EGFP-CB1RWT. Two-way ANOVA with Tukey’s post hoc test. N = ten
independent experiments; n = 80–88 neurons per condition. Axons, WT vs. DH9: mean ± SEM, 1 ± 0.028 vs.
0.765 ± 0.029; N = 10, n = 80 vs. N = 10, n = 88; ****p < 0.0001. Dendrites, WT vs. DH9: mean ± SEM,
0.335 ± 0.016 vs. 0.247 ± 0.017; N = 10, n = 80 vs. N = 10, n = 88; *p = 0.0392. (D) Quantification of data shown in
(B). Endocytosis of EGFP-CB1RDH9 is significantly increased compared to EGFP-CB1RWT in both axons and
dendrites. One-way ANOVA with Tukey’s post hoc test. N = seven independent experiments; n = 49 neurons per
condition. Axons, WT vs. DH9: mean ± SEM, 1.00 ± 0.058 vs. 1.38 ± 0.08; **p = 0.0026. Dendrites, WT vs. DH9:
mean ± SEM, 0.689 ± 0.05 vs. 1.225 ± 0.105; ****p < 0.0001. (E) Quantification of data shown in (A) presented as
the surface polarity index. There was no difference in surface polarity between EGFP-CB1RWT or EGFP-CB1RDH9.
Mann-Whitney test. N = ten independent experiments; n = 80–88 neurons per condition. WT vs. DH9:
mean ± SEM, 3.298 ± 0.1812 vs. 3.915 ± 0.3367; N = 10, n = 80 vs. N = 10, n = 88; p = 0.6886.
DOI: https://doi.org/10.7554/eLife.44252.008
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Figure 7. Role of H9 in CB1R signalling and in resisting agonist-induced endocytosis. (A) Representative blots
showing ERK1/2 phosphorylation in HEK293T cells expressing EGFP-CB1RWT or EGFP-CB1RDH9 following vehicle
(0.1% EtOH) or ACEA (1 mM) treatment for 5 min. (B) Quantification of data shown in (A). Following treatment with
ACEA, ERK1/2 was significantly more phosphorylated in EGFP-CB1RWT- and EGFP-CB1RDH9-transfected cells
Figure 7 continued on next page
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Our results further demonstrate that ctCB1R is important for maintaining axonal surface polarity,
in part mediated by the H9 motif, which plays a role in both the preferential delivery and selective
retention of CB1R at in axons. We show that deleting H9 (CB1RDH9) has a range of effects on traffick-
ing, surface expression, and signalling in hippocampal neurons. More specifically, these include; i)
CB1RDH9 lacks the preferential delivery to axons observed for CB1RWT, ii) CB1RDH9 is less efficiently
surface expressed, iii) CB1RDH9 that does reach the surface it is more rapidly endocytosed in both
axons and dendrites, and iv) CB1RDH9 is more sensitive to agonist-induced internalisation and less
efficient at downstream signalling, monitored by activation of ERK1/2 phosphorylation.
Preferential axonal trafficking
The mechanism behind polarised membrane trafficking in neurons is a fundamental question and
our data suggest a sorting mechanism at the level of the secretory pathway that preferentially tar-
gets CB1R to the axon. Since dendritic and axonal cargo are synthesized in the somatodendritic
compartment, selective sorting to the correct domain is crucial. While several sorting signals and
adaptors have been described for dendritic cargo, the mechanisms behind selective sorting to axons
are less well known (Lasiecka and Winckler, 2011; Bentley and Banker, 2016). For example, a
recent study in C. elegans has suggested that sorting of cargos to axons or dendrites depends on
binding to different types of clathrin-associated adaptor proteins (AP); axonal cargo bind to AP-3
whereas dendritic cargo bind to AP-1 (Li et al., 2016). Interestingly, AP-3 binding has been associ-
ated with CB1R trafficking to the lysosome in the dendritic compartment (Rozenfeld and Devi,
2008). One possibility is that H9 may modulate CB1R binding to AP-3, allowing for preferential
delivery to axons and sorting to dendritic lysosomes, causing an decrease in dendritic membrane
CB1R. More studies are needed to examine the possibility of H9 influencing AP-3 and CB1R
interaction.
Trafficking within the axon
We used time-resolved RUSH experiments to investigate the initiation of CB1R polarity. We mea-
sured the transit through the secretory pathway and incorporation into, and passage through, the
highly organised axon initial segment (AIS) that acts as a ‘gate-keeper’ for proteins entering the axo-
nal compartment. Our data show that CB1R polarisation was initiated in the first 90 min since they
were directly targeted to, and surface expressed within, proximal axonal regions.
Figure 7 continued
compared to untransfected cells. However, ERK1/2 activation was significantly reduced in EGFP-CB1RDH9-
expressing cells compared to EGFP-CB1RWT-expressing cells. There was no significant difference in ERK1/2
phosphorylation in vehicle-treated cells. Two-way ANOVA with Tukey’s post hoc test. N = three independent
experiments. ACEA, WT vs. Control: mean ± SEM, 7.17 ± 0.684 vs. 1.21 ± 0.252; ****p < 0.0001. DH9 vs. Control:
mean ± SEM, 3.57 ± 0.825 vs. 1.21 ± 0.252; *p = 0.0150. WT vs. DH9: mean ± SEM, 7.17 ± 0.684 vs. 3.57 ± 0.825;
***p = 0.0007. EtOH, WT vs. DH9 vs. Control: nsp  0.9125. (C) Quantification of data shown in (A). EGFP-CB1RWT
and EGFP-CB1RDH9 expressed equally in HEK293T cells. Two-way ANOVA with Sidak’s post hoc test. Three
independent experiments. (nsp  0.9654). (D) Representative immunoblots from surface biotinylation experiments
showing surface and total fractions of EGFP-CB1RWT and EGFP-CB1RDH9 in HEK293T cells. (E) Quantification of
data shown in (D). EGFP-CB1RWT and EGFP-CB1RDH9 are surface expressed at equivalent levels in HEK293T cells.
Unpaired t-test. Eight independent experiments. WT vs. DH9: mean ± SEM, 1.00 ± 0.0974 vs. 0.885 ± 0.0549; nsp =
0.3212. (F) Representative confocal images of DIV 12 hippocampal neurons expressing EGFP-CB1RWT or EGFP-
CB1RDH9 and treated with vehicle (0.1% EtOH) or CB1R agonist (5 mM ACEA) for 3 hr. Upper panels for each
condition show whole cell field of view and lower panels are enlargements of axonal (a) and dendritic (d) ROIs.
Green = total; magenta = surface; blue = axon marker (Ankyrin-G). Merge: surface to total seen as white. (G)
Quantification of data represented in (F). Significantly less EGFP-CB1RDH9 than EGFP-CB1RWT remained on the
surface of axons after agonist application, indicating greater sensitivity to agonist-induced internalisation. The
surface mean fluorescence was first normalised to the total mean fluorescence for each ROI, then to the average
axonal EtOH value within a condition (set to 100%). Unpaired t-test. N = three independent experiments; n = 23–
24 neurons per condition. WT vs. DH9: mean ± SEM, 64 ± 6.42 vs. 40.6 ± 4.87; N = 3, n = 24 vs. N = 3, n = 23;
**p = 0.0059.
DOI: https://doi.org/10.7554/eLife.44252.009
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Figure 8. The role of H9 in polarity is revealed in the presence of inverse agonist. (A) Representative confocal
images of DIV 14 hippocampal neurons expressing EGFP-CB1RWT or EGFP-CB1RDH9 and treated with vehicle
(0.2% DMSO) or CB1R inverse agonist (10 mM AM281) for 3 hr. Upper panels for each condition show whole cell
field of view and lower panels are enlargements of axonal (a) and dendritic (d) ROIs. Green = total;
magenta = surface; blue = axon marker (Ankyrin-G). Merge: surface to total seen as white. (B) Quantification of
data shown in (A) presented as the surface polarity index (A/D ratio). In the presence of inverse agonist, but not
vehicle, EGFP-CB1RDH9 was significantly less axonally polarised than EGFP-CB1RWT. Two-way ANOVA with Sidak’s
post hoc test. N = three independent experiments; n = 18–22 neurons per condition. DMSO, WT vs. DH9:
mean ± SEM, 2.17 ± 0.135 vs. 2.34 ± 0.196; N = 3, n = 22 vs. N = 3, n = 22; nsp = 0.9605. AM281, WT vs. DH9:
mean ± SEM, 2.2 ± 0.18 vs. 1.41 ± 0.0649; N = 3, n = 19 vs. N = 3, n = 18; **p = 0.0067. (C) Quantification of data
represented in (A). Significantly more EGFP-CB1RDH9 than EGFP-CB1RWT relocated to the surface of dendrites
after inverse agonist application. The surface mean fluorescence was first normalised to the total mean
fluorescence for each ROI, then to the average DMSO value within a condition (set to 100%). Unpaired t-test.
N = three independent experiments; n = 18–19 neurons per condition. WT vs. DH9: mean ± SEM, 122 ± 12.2 vs.
215 ± 11.3; N = 3, n = 19 vs. N = 3, n = 18; ****p < 0.0001.
DOI: https://doi.org/10.7554/eLife.44252.010
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Immunocytochemistry in brain sections using immunogold electron microscopy (Katona et al.,
1999; Nyı´ri et al., 2005) or STORM super-resolution imaging (Dudok et al., 2015) detect CB1R pre-
dominantly at the presynaptic terminal, consistent with a disto-proximal gradient of expression at
the axonal plasma membrane (Simon et al., 2013). Therefore, given the highly branched morphol-
ogy of typical CB1R expressing neurons, correct axonal polarization likely requires specific distal tar-
geting mechanisms in addition to the processes we describe using time-resolved RUSH experiments.
CB1Rs are highly mobile and diffuse rapidly in the plasma membrane (Mikasova et al., 2008;
Oddi et al., 2012), so the accumulation of surface CB1R we observe may be followed by lateral dif-
fusion and ‘capture’ of surface CB1R at presynaptic sites, analogous to the diffusion and retention
Figure 9. Schematic summarising main findings. Polarised surface distribution of CB1R is established and
maintained by two complementary mechanisms: (Ai) selective delivery of newly synthesized CB1R to the axon (or
restricted delivery to dendrites) and (Aii) selective retention in axons and retrieval from dendrites. The C-terminal
motif Helix 9 plays a role in both of these mechanisms because deletion of H9 leads to: (Bi) a loss of axon-
selective delivery and (Bii) reduced retention in both axons and dendrites that can be reversed in dendrites by
inverse agonist application, suggesting that CB1RDH9 is more susceptible to activity-driven internalisation.
DOI: https://doi.org/10.7554/eLife.44252.011
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models proposed for AMPARs and GABAARs at the postsynaptic membrane (Hastings and Man,
2018; Kneussel and Hausrat, 2016). Another, non-exclusive possibility is that CB1R-containing
vesicles originating from the secretory system and/or endosomal system traffic to distal sites inside
the axon (Lasiecka and Winckler, 2011). Indeed, it has been reported that CB1R in somatodendritic
endosomes can be rerouted and trafficked to distal axonal surfaces (Simon et al., 2013). Our obser-
vation that intracellular CB1R is present at least 100 mm along the axon before it appears at the sur-
face supports the concept of a rapid and direct trafficking of CB1R-containing secretory vesicles to
more distal areas of the axon, although more detailed tracking of these secretory vesicles to presyn-
aptic boutons would be required to confirm this. Overall, we interpret our data to suggest that
arrival at, and progression through, the AIS constitutes the initial phase of CB1R axonal polarisation.
Once within the axonal compartment trafficking to more distal locations and to presynaptic sites is
then mediated by additional mechanisms that probably include both intracellular transport and lat-
eral diffusion and trapping.
H9 and membrane retention
Our data suggest that H9 stabilises CB1R at the membrane, regardless of compartment. While the
H8 domain is highly conserved in GPCRs, structural domains analogous to H9 have only been
reported in squid rhodopsin (Murakami and Kouyama, 2008) and the bradykinin receptor
(Piserchio et al., 2005). NMR and circular dichroism studies suggest that H9, like H8, is an amphi-
pathic a-helix, associating with the lipid bilayer via a cluster of hydrophobic residues on the non-
polar face of the helix (Ahn et al., 2009). Furthermore, CB1R has been shown to be palmitoylated
just downstream of H8 at C416, which affects its membrane association and G-protein coupling
(Oddi et al., 2012; Oddi et al., 2018). H9 also contains a cysteine residue, raising the possibility
that post-translational modifications such as palmitoylation, prenylation, or farnesylation at this site
could modulate membrane association.
Since our data suggest that H9 stabilises CB1R at the membrane, it is possible that the mem-
brane association of H9 could mask internalisation signals or interacting motifs. Consistent with this
possibility, ctCB1R interacting proteins regulate CB1R endocytosis. For example, SGIP1, a protein
linked to clathrin-mediated endocytosis, binds at an as yet undefined site on ctCB1R downstream of
H8, preventing internalisation of activated CB1R (Ha´jkova´ et al., 2016). Similarly, cannabinoid
receptor interacting protein 1a (CRIP1a), which interacts directly with a motif in the last 9 C-terminal
amino acids (Niehaus et al., 2007), reduces constitutive CB1R internalisation (Mascia et al., 2017)
by competing with b-Arrestin binding (Blume et al., 2017). Therefore, it is possible that H9 mediates
the interactions between CB1R and SGIP1 and/or selectively promotes b-Arrestin rather than CRIP1a
binding. Further studies examining the interaction between CB1RWT, CB1RDH9, CRIP1a, b-Arrestin1/
2, and SGIP1 are needed to examine the mechanism by which H9 stabilises surface CB1R.
Given the increased interest in CB1R as a clinical target, understanding the fundamental cell biol-
ogy and trafficking behaviour of CB1R is an increasingly active and important area of research. Taken
together, our results reveal that the C-terminal domain, and H9 in particular, play important roles in
trafficking of CB1R. These findings provide important insight into the mechanisms of CB1R polarity
and highlight H9 as an important regulator of CB1R endocytosis and surface expression.
Materials and methods
Key resources table
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Antibody anti-GFP
(chicken polyclonal)
Abcam Abcam:ab13970;
RRID:AB_300798
ICC (1:1,000)
Antibody anti-GFP
(rat monoclonal;
clone 3H9)
Chromotek Chromotek:3h9-100;
RRID:AB_10773374
WB
(1:2,000-1:5,000)
Antibody anti-Ankyrin-G
(mouse monoclonal;
purified; clone N106/36)
NeuroMab NeuroMab:75–146;
RRID:AB_10673030
ICC (1:500)
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Antibody anti-CD4
(mouse monoclonal;
purified; clone OKT4)
BioLegend BioLegend:
317402; RRID:AB_571963
ICC (1:400)
Antibody anti-MAP2
(rabbit polyclonal)
Synaptic
Systems
SySy:188 003;
RRID:AB_2281442
ICC (1:500)
Antibody anti-MAP Kinase,
Activated/
monophosphorylated,
Phosphothreonine
ERK-1 and 2
(mouse monoconal;
clone ERK-PT115)
Merck
(Sigma-Aldrich)
Sigma-Aldrich:
M7802; RRID:AB_260658
WB (1:1,000)
Antibody anti-MAP Kinase,
Non-Phosphorylated
ERK (mouse monoclonal;
clone ERK-NP2)
Merck
(Sigma-Aldrich)
Sigma-Aldrich:
M3807; RRID:AB_260501
WB (1:250)
Antibody anti-GAPDH
(mouse monoclonal;
clone 6C5)
Abcam Abcam:ab8245;
RRID:AB_2107448
WB (1:20,000)
Antibody
(secondary)
Peroxidase
anti-mouse
IgG (goat)
Merck
(Sigma-Aldrich)
Sigma-Aldrich:
A3682
WB (1:10,000)
Antibody
(secondary)
Peroxidase
anti-rat IgG
(rabbit)
Merck
(Sigma-Aldrich)
Sigma-Aldrich:
A5795
WB (1:10,000)
Antibody
(secondary)
Cy2 anti-chicken
IgY (donkey)
Jackson Immuno
Research (Stratech)
JIR:703-225-155;
RRID:AB_2340370
ICC (1:400)
Antibody
(secondary)
Alexa Fluor 647
anti-chicken
IgY (donkey)
Jackson Immuno
Research (Stratech)
JIR:703-606-155;
RRID:AB_2340380
ICC (1:400)
Antibody
(secondary)
Cy3 anti-chicken
IgY (donkey)
Jackson Immuno
Research (Stratech)
JIR:703-165-155;
RRID:AB_2340363
ICC (1:400)
Antibody
(secondary)
Cy5 anti-mouse
IgG (donkey)
Jackson Immuno
Research (Stratech)
JIR:715-175-150;
RRID:AB_2340819
ICC (1:400)
Antibody
(secondary)
Cy3 anti-mouse
IgG (donkey)
Jackson Immuno
Research (Stratech)
JIR:715-165-150;
RRID:AB_2340813
ICC (1:400)
Antibody
(secondary)
DyLight 405
anti-mouse
IgG (goat)
Jackson Immuno
Research (Stratech)
JIR:115-475-003;
RRID:AB_2338786
ICC (1:400)
Antibody
(secondary)
Alexa Fluor
488 anti-rabbit
IgG (donkey)
Jackson Immuno
Research (Stratech)
JIR:711-545-152;
RRID:AB_2313584
ICC (1:400)
Chemical
compound, drug
Arachidonyl-2’-
chloroethylamide
(ACEA)
Bio-Techne (Tocris) Tocris:1319
Chemical
compound,
drug
AM 281 Bio-Techne (Tocris) Tocris:1115 Dissolved in DMSO
Cell line
(H. sapiens)
HEK293T ECACC (Sigma-Aldrich) ECACC:12022001;
RRID:CVCL_0063
Cell line
(R. norvegicus)
primary
hippocampal neurons
University of Bristol
Animal Services Unit
E18 Wistar Han rats
Recombinant
DNA reagent
pIRESneo3_Str-
KDEL_IRES-SPIl-2-
SBP-mCherry-
Ecadherin (plasmid)
PMID:22406856 Addgene:65287
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Recombinant
DNA reagent
pcDNA1-SPHgH-
SEP-CB1RWT (plasmid)
PMID:17467290
Recombinant
DNA reagent
pcDNA1-SPHgH-
SEP-CB1RDH9 (plasmid)
This paper PCR mutagenesis
template:
pcDNA1-SPHgH-
SEP-CB1RWT
Recombinant
DNA reagent
pIRESneo3_Str-KDEL_IRES-
SPIl-2-SBP-EGFP-CB1RW
T (plasmid)
This paper PCR template:
pcDNA1-SPHgH-
SEP-CB1R
Vector: pIRESneo3
_Str-KDEL_
IRES-SPIl-2-SBP-mCherry-
Ecadherin
Recombinant
DNA reagent
pIRESneo3_Str-KDEL_
IRES-SPIl-2-SBP-
EGFP-CB1RDH9 (plasmid)
This paper PCR template:
pcDNA1-SPHgH-
SEP-CB1RDH9
Vector:
pIRESneo3_
Str-KDEL_
IRES-SPIl-2-SBP-
mCherry-Ecadherin
Recombinant
DNA reagent
pcDNA3.1-SPIl-2-
SBP-EGFP-CB1RWT (plasmid)
This paper PCR template:
pIRESneo3_
Str-KDEL_
IRES-SPIl-2-SBP-
EGFP-CB1RWT
Vector: pcDNA3.1(+)
Recombinant
DNA reagent
pcDNA3.1-SPIl-2-SBP
-EGFP-CB1RDH9 (plasmid)
This paper PCR template:
pIRESneo3_Str-
KDEL_IRES-SPIl-2-
SBP-EGFP-CB1RDH9
Vector: pcDNA3.1(+)
Recombinant
DNA reagent
pcDNA3.1-SPIl-2-
EGFP-CB1RWT (plasmid)
This paper PCR mutagenesis
template:
pcDNA3.1-SPIl-2-
SBP-EGFP-CB1RWT
Recombinant
DNA reagent
pcDNA3.1-SPIl-2-
EGFP-CB1RDH9 (plasmid)
This paper PCR mutagenesis
template: pcDNA3.1
-SPIl-2-SBP-
EGFP-CB1RDH9
Recombinant
DNA reagent
pCB6-CD4DCt (plasmid) PMID:11689435
Recombinant
DNA reagent
pCB6-CD4-
ctCB1RWT (plasmid)
This paper Overlap extension
PCR template:
pcDNA1-SPHgH-
SEP-CB1RWT
Vector: pCB6-CD4DCt
Recombinant
DNA reagent
pCB6-CD4-
ctCB1RDH9 (plasmid)
This paper Overlap extension
PCR template:
pcDNA1-SPHgH-
SEP-CB1RDH9
Vector: pCB6-CD4DCt
Chemical
compound, drug
Neurobasal Thermo Fisher
Scientific (Gibco)
TFS:21103049
Chemical
compound, drug
Horse Serum Merck
(Sigma-Aldrich)
Sigma-Aldrich:
H1270
Chemical
compound, drug
B27 Thermo Fisher
Scientific (Gibco)
TFS:A3582801
Chemical
compound, drug
GS21 MTI GlobalStem GS:3100
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Chemical
compound, drug
GlutaMAX Thermo Fisher
Scientific (Gibco)
TFS:35050038
Chemical
compound, drug
DMEM Lonza Lonza:12–614F
Chemical
compound, drug
L-Glutamine Merck
(Sigma-Aldrich)
Sigma-Aldrich:
G7513
Chemical
compound, drug
FBS Merck
(Sigma-Aldrich)
Sigma-Aldrich:
F7524
Chemical
compound, drug
Lipofectamine 2000 Thermo
Fisher Scientific
TFS:11668019
Chemical
compound, drug
D-Biotin Merck
(Sigma-Aldrich)
Sigma-Aldrich:
B4501
Chemical
compound, drug
EZ-Link Sulfo-
NHS-SS-Biotin
Thermo
Fisher Scientific
TFS:21331
Chemical
compound, drug
Streptavidin 
Agarose
Merck
(Millipore)
Merck:S1638
Chemical
compound, drug
Bovine Serum
Albumin
Thermo
Fisher Scientific
TFS:BP9704
Chemical
compound, drug
Fluoromount-G Thermo
Fisher Scientific
TFS:00-4958-02
Chemical
compound, drug
cOmplete Protease
Inhibitor Cocktail
Merck
(Sigma-Aldrich)
Sigma-Aldrich:
11697498001
Chemical
compound, drug
Pierce Phosphatase
Inhibitor
Thermo
Fisher Scientific
TFS:A32957
Chemical
compound, drug
CHAPS Detergent Thermo
Fisher Scientific
TFS:28300
Software,
algorithm
GraphPad Prism GraphPad Prism
(https://graphpad.com)
RRID:SCR_002798 Version 7
Software,
algorithm
Fiji Fiji (https://fiji.sc/) RRID:SCR_002285
Constructs and reagents
A previously characterised rat CB1R construct in which the first 25 N-terminal amino acids were omit-
ted to avoid possible cleavage of the SBP-EGFP tag (McDonald et al., 2007b; Nordstro¨m and
Andersson, 2006) was used as a template for sub-cloning into pcDNA3.1. This construct displays
normal plasma membrane trafficking (McDonald et al., 2007b; Hebert-Chatelain et al., 2016) and
removes the region reported to constitute a mitochondrial targeting motif (Hebert-Chatelain et al.,
2016). Helix 9 (residues 440–460) was removed by site-directed mutagenesis. These WT and DH9
constructs were subsequently used as a template to clone into the RUSH vector system (interleukin-2
signal peptide followed by SBP and EGFP N-terminal tags) as previously described (Evans et al.,
2017; Boncompain and Perez, 2013). Non-ER-retained SBP-EGFP-tagged versions were obtained
by re-cloning these inserts from the RUSH vector into pcDNA3.1 (pcDNA-SPIl-2-SBP-EGFP-CB1R).
The SBP tag was deleted for surface biotinylation experiments by site-directed mutagenesis
(pcDNA-SPIl-2-EGFP-CB1R). Chimeric CD4-ctCB1R WT and DH9 were generated by overlap extension
PCR followed by cloning into a plasmid expressing CD4 lacking its own C-terminus (Garrido, 2001).
Chicken anti-GFP was from Abcam (ab13970); mouse anti-Ankyrin-G was from NeuroMab (clone
N106/36); rabbit anti-MAP2 was from Synaptic Systems (188 003); mouse anti-CD4 was from BioLe-
gend (clone OKT4); rat anti-GFP was from ChromoTek (3H9); anti-phosphoERK (M7802), and anti-
non-phosphoERK (M3807) were from Sigma; mouse anti-GAPDH (6C5 ab8245) was from Abcam. All
fluorescent secondaries were from Jackson Immunoresearch Laboratories and HRP conjugated
secondaries were from Sigma. ACEA and AM281 were from Tocris bio-techne.
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Cell culture and transfection
Dissociated hippocampal cultures were prepared from E17-E18 Wistar rats as previously described
(Martin and Henley, 2004). Glass coverslips were coated in poly-D-lysine or poly-L-lysine (1 mg/mL,
Sigma) in borate buffer (10 mM borax, 50 mM boric acid) overnight and washed in water. Dissoci-
ated hippocampal cells were plated at different densities in plating medium (Neurobasal, Gibco sup-
plemented with 10% horse serum, Sigma; 2 mM GlutaMAX, Gibco; and either GS21, GlobalStem, or
B27, Thermo Fisher) which was changed to feeding medium (Neurobasal supplemented with 1.2
mM GlutaMAX and GS21 or B27) after 24 hr. For RUSH experiments, cells were plated and fed in
media containing GS21 instead of B27 because it does not contain biotin. Cells were incubated at
37˚C and 5% CO2 for up to 2 weeks. Animal care and procedures were carried out in accordance
with UK Home Office and University of Bristol guidelines.
Transfection of neuronal cultures was carried out at DIV 12 using Lipofectamine2000 (Invitrogen)
according to the manufacturer’s instructions with minor modifications. Cells were left for 20–48 hr
before fixation.
HEK293T cells (ECACC) were passaged and maintained in complete DMEM (DMEM + 10%
FBS + 2 mM L-Glutamine). HEK293T cells were regularly treated with ciprofloxacin (10 mg/mL) to
prevent mycoplasma contamination.
Phospho-ERK assay
HEK293T cells were transfected with SBP-EGFP-CB1RWT, SBP-EGFP-CB1RDH9, or empty pcDNA3.1
and left for 24 hr. The cells were serum-starved overnight and then treated with 1 mM ACEA or
0.01% EtOH for 5 min before being lysed in lysis buffer (50 mM Tris-HCl; 150 mM NaCl; 1% CHAPS,
ThermoFisher Scientific; protease inhibitors, Roche) with phosphatase inhibitors (Pierce, Thermo-
Fisher Scientific). SDS-PAGE and Western blotting procedures were carried out according to stan-
dard protocols.
Surface biotinylation assay
HEK293T cells were transfected with EGFP-CB1RWT or EGFP-CB1RDH9 for 48 hr, then cooled to 4˚C
on ice and washed 3 times in ice-cold PBS. 0.3 mg/mL of EZ-Link Sulfo-NHS-SS-Biotin in PBS was
added for 10 min, then the cells were washed 3 times in PBS. 50 mM NH4Cl in PBS was added for 2
min to quench any remaining unreacted biotin, and the cells were washed another 3 times in PBS
before being lysed in lysis buffer. Biotinylated surface proteins were isolated using streptavidin
coated agarose beads according to standard protocols.
Live surface staining and antibody feeding
To measure surface staining, cultured neurons were cooled at room temperature for 5–10 min, then
incubated with the appropriate antibody (chicken anti-GFP or mouse anti-CD4) in conditioned media
for 10–20 min at RT. The neurons were washed multiple times in PBS before fixation.
For agonist and inverse agonist experiments, the neurons were treated with 5 mM ACEA (in
EtOH) or vehicle control (0.1% EtOH) for 3 hr or 10 mM AM281 (in DMSO) or vehicle control (0.2%
DMSO) for 3 hr in conditioned media at 37˚C and 5% CO2, and then subsequently surface stained.
To measure endocytosed receptors, neurons were fed with the appropriate antibody (chicken
anti-GFP or mouse anti-CD4) for 2 hr in conditioned media at 37˚C and 5% CO2. Neurons were
washed several times in PBS and then surface antibody was stripped by two quick washes with ice-
cold pH 2.5 PBS (anti-GFP) or a 4 min incubation with 0.5M NaCl and 0.2M acetic acid (anti-CD4) fol-
lowed by several washes in PBS before fixation.
RUSH live labelling
Neurons were transfected with RUSH constructs at DIV 12 for no longer than 24 hr to prevent ER
stress resulting from accumulation of unreleased receptors. Neurons were incubated in conditioned
media containing D-biotin (40 mM, Sigma) and chicken anti-GFP (1:1,000) for different lengths of
time at 37˚C and 5% CO2. The 0 min timepoint was only incubated with chicken anti-GFP without
biotin for 60 min. For the O/N timepoint, neurons were incubated in 40 mM D-biotin immediately fol-
lowing transfection and then left overnight at 37˚C and 5% CO2 before being incubated with biotin
and chicken anti-GFP for 60 min to label surface CB1R. Every independent experiment included a 60
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min timepoint to which values were normalised and a 0 min control. Following biotin treatment, neu-
rons were washed several times in PBS and cooled to 4˚C to prevent further internalisation. They
were then live labelled with 647-labelled anti-chicken in conditioned media for 15 min at 4˚C before
being fixed and permeabilised and stained with Cy3-labelled anti-chicken. In the text, ‘surface’ thus
refers to 647 fluorescence acquisition, whereas ‘surface + endocytosed’ refers to Cy3 fluorescence
acquisition.
Fixation and fixed immunostaining
Cultured neurons were fixed in 4% formaldehyde in PBS for 12 min, then washed 3x in PBS, 1x in
100 mM Glycine in PBS, and 3x in PBS. The neurons were then blocked and permeabilised in
PBS + 3% BSA + 0.1% Triton X-100 before being incubated in fluorescent secondary (1:400) in
PBS + 3% BSA. Subsequently, the neurons were re-incubated in primary antibody (anti-GFP or anti-
CD4) to measure total levels of expression and stained with either anti-MAP2 (dendritic marker) or
anti-Ankyrin-G (axonal initial segment marker) in PBS + 3% BSA. The neurons were then washed sev-
eral times in PBS and mounted onto glass slides using Fluoromount-G (ThermoFisher Scientific).
Image acquisition and analysis
Images were acquired using either a Leica SPE single channel confocal laser scanning microscope or
a Leica SP8 AOBS confocal laser scanning microscope (Wolfson Bioimaging Facility, University of
Bristol). All settings were kept the same within experiments. Neurons used for data acquisition were
selected only on their total staining.
All quantification was performed using FIJI (ImageJ) software. Based on previous experiments, at
least five cells were analysed per experiment, and at least three independent experiments (i.e. on
different neuronal cultures on different days) were performed.
Images were max projected, and regions of interest (ROIs) of approximately similar lengths were
drawn around axons and 3–4 proximal and secondary dendrites based on the total channel only.
Axons were defined either as processes whose initial segment was positive for Ankyrin-G or as pro-
cesses negative for MAP2. The mean fluorescence was measured for each channel and the dendritic
values were averaged. ‘Surface’ or ‘endocytosed’ mean fluorescence values were normalised to the
‘total’ mean fluorescence value for each ROI to account for varying levels of expression of trans-
fected constructs. These values were then normalised to the axon value of the control (WT or CD4).
For drug treatments, surface values were normalised to their respective vehicle treated controls and
sampled at the same time-point (i.e. WT + drug was normalised to WT + vehicle and DH9 + drug
was normalised to DH9 + vehicle) to account for possible differences in steady-state surface expres-
sion between the constructs and/or constitutive internalisation.
Because of the change in total mean fluorescence in axons throughout the different conditions,
the above image analysis was slightly modified for RUSH experiments. In these experiments, neurites
were traced using NeuronJ so that only the mean fluorescence of exactly the first 50 mm of the axons
and 30–40 mm of 2–4 primary dendrites for each channel was measured. All ‘surface’ and
‘surface + endocytosed’ values (of both axons and dendrites) were normalised to the average total
dendritic value for each neuron. Axon total mean fluorescence was also normalised to the average
total dendritic value within each cell. All values were then normalised to the WT 60 min axon value
within each experiment. In a slightly smaller subset of RUSHed neurons, axons were traced for ~100
mm using NeuronJ. Line plots were generated and the mean fluorescence was averaged in 10 mm
segments. The averages for each 10 mm segment from each cell were normalised first to the den-
dritic total value, then to the axonal 60 min value of the first 50 mm.
Polarity indices (A/D ratio) were calculated by dividing the axonal mean fluorescence value by the
average dendritic mean fluorescence value.
The scalebar for all images represents 20 mm.
Statistics
All statistics were performed using GraphPad Prism. The ROUT method was used to identify outliers
for all parameters measured before normalising to control. Neurons were removed from analysis if
any one parameter was found to be an outlier. As is the convention in the field (Leterrier et al.,
2006; Coutts et al., 2001; Simon et al., 2013; Evans et al., 2017; McDonald et al., 2007b;
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Leterrier et al., 2017), ‘N’ denotes the number of separate neuronal cultures prepared from litters
of pups from separate dams and ‘n’ denotes the total number of neurons across the separate cul-
tures assessed. To determine statistical significance between two groups, a D’Agostino and Pearson
normality test was performed. Unpaired t-tests were performed on data that passed the normality
test whereas the Mann-Whitney test was used if it did not. One- or Two-way ANOVAs with Tukey’s
or Sidak’s post hoc test were used to determine statistical significance between more than two
groups depending on the comparisons required. *p  0.05, **p  0.01, ***p  0.001,
****p  0.0001. All data are presented as mean ± SEM.
Acknowledgements
We are grateful to the Wellcome Trust for financial support. AFJ is funded by a University of Bristol
PhD Scholarship. We thank F Perez and G Boncompain (Institut Curie, Paris) for the RUSH constructs,
A Irvine (University of Dundee) for template CB1R plasmids and B Dargent (Universite´ de la Mediter-
rane´e, Marseille) for CD4 plasmids. We gratefully acknowledge the excellent Wolfson Bioimaging
Facility at the University of Bristol, supported by the BBSRC.
Additional information
Funding
Funder Author
Wellcome Ashley J Evans
Medical Research Council Kevin A Wilkinson
Jeremy M Henley
Biotechnology and Biological
Sciences Research Council
Kevin A Wilkinson
Jeremy M Henley
University of Bristol Alexandra Fletcher-Jones
The funders had no role in study design, data collection and
interpretation, or the decision to submit the work for publication.
Author contributions
Alexandra Fletcher-Jones, Conceptualization, Data curation, Formal analysis, Investigation, Method-
ology, Writing—review and editing; Keri L Hildick, Conceptualization, Investigation, Methodology;
Ashley J Evans, Conceptualization, Methodology, Project administration, Writing—review and edit-
ing; Yasuko Nakamura, Resources, Methodology, Project administration; Kevin A Wilkinson, Concep-
tualization, Supervision, Funding acquisition, Writing—review and editing; Jeremy M Henley,
Conceptualization, Supervision, Funding acquisition, Writing—original draft, Project administration,
Writing—review and editing
Author ORCIDs
Alexandra Fletcher-Jones http://orcid.org/0000-0002-6192-2901
Ashley J Evans http://orcid.org/0000-0002-6658-2176
Kevin A Wilkinson https://orcid.org/0000-0002-8115-8592
Jeremy M Henley http://orcid.org/0000-0003-3589-8335
Ethics
Animal experimentation: The use of animals is unavoidable because there is no satisfactory alterna-
tive preparation for studying neuronal and synaptic mechanisms that do not involve the use of tissue
acutely removed from animals. All experiments in this study were designed to ensure the use of min-
imum numbers of animals which were sacrificed by cervical dislocation in strict accordance with UK
Home Office Schedule 1 guidelines using procedures approved by the Animal Welfare and Ethics
Review Body (AWERB) at the University of Bristol (approval reference number UIN UB/18/004).
Fletcher-Jones et al. eLife 2019;8:e44252. DOI: https://doi.org/10.7554/eLife.44252 23 of 26
Research article Neuroscience
Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.44252.014
Author response https://doi.org/10.7554/eLife.44252.015
Additional files
Supplementary files
. Transparent reporting form
DOI: https://doi.org/10.7554/eLife.44252.012
Data availability
All relevant data are included in this published article. None of the data was suitable for depositing
in repositories and no new software was generated.
References
Ahn KH, Pellegrini M, Tsomaia N, Yatawara AK, Kendall DA, Mierke DF. 2009. Structural analysis of the human
cannabinoid receptor one carboxyl-terminus identifies two amphipathic helices. Biopolymers 91:565–573.
DOI: https://doi.org/10.1002/bip.21179, PMID: 19274719
Ahn KH, Nishiyama A, Mierke DF, Kendall DA. 2010. Hydrophobic residues in helix 8 of cannabinoid receptor 1
are critical for structural and functional properties. Biochemistry 49:502–511. DOI: https://doi.org/10.1021/
bi901619r, PMID: 20025243
Atwood BK, Lopez J, Wager-Miller J, Mackie K, Straiker A. 2011. Expression of G protein-coupled receptors and
related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics
12:14. DOI: https://doi.org/10.1186/1471-2164-12-14, PMID: 21214938
Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S. 2017. Endocannabinoid system in neurodegenerative
disorders. Journal of Neurochemistry 142:624–648. DOI: https://doi.org/10.1111/jnc.14098, PMID: 28608560
Bentley M, Banker G. 2016. The cellular mechanisms that maintain neuronal polarity. Nature Reviews
Neuroscience 17:611–622. DOI: https://doi.org/10.1038/nrn.2016.100, PMID: 27511065
Blume LC, Patten T, Eldeeb K, Leone-Kabler S, Ilyasov AA, Keegan BM, O’Neal JE, Bass CE, Hantgan RR,
Lowther WT, Selley DE, Howlett AL. 2017. Cannabinoid receptor interacting protein 1a competition with b-
Arrestin for CB1 receptor binding sites. Molecular Pharmacology 91:75–86. DOI: https://doi.org/10.1124/mol.
116.104638, PMID: 27895162
Boncompain G, Divoux S, Gareil N, de Forges H, Lescure A, Latreche L, Mercanti V, Jollivet F, Raposo G, Perez
F. 2012. Synchronization of secretory protein traffic in populations of cells. Nature Methods 9:493–498.
DOI: https://doi.org/10.1038/nmeth.1928
Boncompain G, Perez F. 2013. Fluorescence-based analysis of trafficking in mammalian cells. Methods in Cell
Biology 118:179–194. DOI: https://doi.org/10.1016/B978-0-12-417164-0.00011-2, PMID: 24295307
Borgdorff AJ, Choquet D. 2002. Regulation of AMPA receptor lateral movements. Nature 417:649–653.
DOI: https://doi.org/10.1038/nature00780, PMID: 12050666
Busquets-Garcia A, Oliveira da Cruz JF, Terral G, Pagano Zottola AC, Soria-Go´mez E, Contini A, Martin H,
Redon B, Varilh M, Ioannidou C, Drago F, Massa F, Fioramonti X, Trifilieff P, Ferreira G, Marsicano G. 2018.
Hippocampal CB1 receptors control incidental associations. Neuron 99:1247–1259. DOI: https://doi.org/10.
1016/j.neuron.2018.08.014, PMID: 30174119
Coutts AA, Anavi-Goffer S, Ross RA, MacEwan DJ, Mackie K, Pertwee RG, Irving AJ. 2001. Agonist-induced
internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. The Journal of
Neuroscience 21:2425–2433. DOI: https://doi.org/10.1523/JNEUROSCI.21-07-02425.2001, PMID: 11264316
Daigle TL, Kearn CS, Mackie K. 2008. Rapid CB1 cannabinoid receptor desensitization defines the time course of
ERK1/2 MAP kinase signaling. Neuropharmacology 54:36–44. DOI: https://doi.org/10.1016/j.neuropharm.2007.
06.005, PMID: 17681354
Dudok B, Barna L, Ledri M, Szabo´ SI, Szabadits E, Pinte´r B, Woodhams SG, Henstridge CM, Balla GY, Nyilas R,
Varga C, Lee SH, Matolcsi M, Cervenak J, Kacskovics I, Watanabe M, Sagheddu C, Melis M, Pistis M, Soltesz I,
et al. 2015. Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid
signaling. Nature Neuroscience 18:75–86. DOI: https://doi.org/10.1038/nn.3892, PMID: 25485758
Evans AJ, Gurung S, Wilkinson KA, Stephens DJ, Henley JM. 2017. Assembly, secretory pathway trafficking, and
surface delivery of kainate receptors is regulated by neuronal activity. Cell Reports 19:2613–2626. DOI: https://
doi.org/10.1016/j.celrep.2017.06.001, PMID: 28636947
Fache MP, Moussif A, Fernandes F, Giraud P, Garrido JJ, Dargent B. 2004. Endocytotic elimination and domain-
selective tethering constitute a potential mechanism of protein segregation at the axonal initial segment. The
Journal of Cell Biology 166:571–578. DOI: https://doi.org/10.1083/jcb.200312155, PMID: 15302857
Garrido JJ. 2001. Identification of an axonal determinant in the C-terminus of the sodium channel Nav1.2. The
EMBO Journal 20:5950–5961. DOI: https://doi.org/10.1093/emboj/20.21.5950
Fletcher-Jones et al. eLife 2019;8:e44252. DOI: https://doi.org/10.7554/eLife.44252 24 of 26
Research article Neuroscience
Ha´jkova´ A, Techlovska´ Sˇ, Dvorˇa´kova´ M, Chambers JN, Kumposˇt J, Huba´lkova´ P, Prezeau L, Blahos J. 2016.
SGIP1 alters internalization and modulates signaling of activated cannabinoid receptor 1 in a biased manner.
Neuropharmacology 107:201–214. DOI: https://doi.org/10.1016/j.neuropharm.2016.03.008, PMID: 26970018
Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F, Koehl M, Abrous DN, Mendizabal-Zubiaga J,
Grandes P, Liu Q, Bai G, Wang W, Xiong L, Ren W, Marsicano G, Zhang X. 2012. Acute cannabinoids impair
working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148:1039–1050.
DOI: https://doi.org/10.1016/j.cell.2012.01.037, PMID: 22385967
Hastings MH, Man HY. 2018. Synaptic capture of laterally diffusing AMPA receptors - An idea that stuck. Trends
in Neurosciences 41:330–332. DOI: https://doi.org/10.1016/j.tins.2018.03.016, PMID: 29801525
Hebert-Chatelain E, Desprez T, Serrat R, Bellocchio L, Soria-Gomez E, Busquets-Garcia A, Pagano Zottola AC,
Delamarre A, Cannich A, Vincent P, Varilh M, Robin LM, Terral G, Garcı´a-Ferna´ndez MD, Colavita M, Mazier W,
Drago F, Puente N, Reguero L, Elezgarai I, et al. 2016. A cannabinoid link between mitochondria and memory.
Nature 539:555–559. DOI: https://doi.org/10.1038/nature20127, PMID: 27828947
Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, Campbell WB.
1999. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor
(CB1). The Journal of Pharmacology and Experimental Therapeutics 289:1427–1433. PMID: 10336536
Hsieh C, Brown S, Derleth C, Mackie K. 1999. Internalization and recycling of the CB1 cannabinoid receptor.
Journal of Neurochemistry 73:493–501. DOI: https://doi.org/10.1046/j.1471-4159.1999.0730493.x, PMID: 1042
8044
Irving AJ, Coutts AA, Harvey J, Rae MG, Mackie K, Bewick GS, Pertwee RG. 2000. Functional expression of cell
surface cannabinoid CB(1) receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons.
Neuroscience 98:253–262. DOI: https://doi.org/10.1016/S0306-4522(00)00120-2, PMID: 10854756
Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, Chavkin C, Mackie K. 1999. Distinct domains of the CB1
cannabinoid receptor mediate desensitization and internalization. The Journal of Neuroscience 19:3773–3780.
DOI: https://doi.org/10.1523/JNEUROSCI.19-10-03773.1999, PMID: 10234009
Katona I, Sperla´gh B, Sı´k A, Ka¨falvi A, Vizi ES, Mackie K, Freund TF. 1999. Presynaptically located CB1
cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. The
Journal of Neuroscience 19:4544–4558. DOI: https://doi.org/10.1523/JNEUROSCI.19-11-04544.1999,
PMID: 10341254
Katona I. 2009. Endocannabinoid receptors: cns localization of the CB1 cannabinoid receptor. Current Topics in
Behavioral Neurosciences 1:65–86. DOI: https://doi.org/10.1007/978-3-540-88955-7_3, PMID: 21104380
Kneussel M, Hausrat TJ. 2016. Postsynaptic neurotransmitter receptor reserve pools for synaptic potentiation.
Trends in Neurosciences 39:170–182. DOI: https://doi.org/10.1016/j.tins.2016.01.002, PMID: 26833258
Ladarre D, Roland AB, Biedzinski S, Ricobaraza A, Lenkei Z. 2014. Polarized cellular patterns of endocannabinoid
production and detection shape cannabinoid signaling in neurons. Frontiers in Cellular Neuroscience 8:426.
DOI: https://doi.org/10.3389/fncel.2014.00426, PMID: 25610369
Lasiecka ZM, Winckler B. 2011. Mechanisms of polarized membrane trafficking in neurons – focusing in on
endosomes. Molecular and Cellular Neuroscience 48:278–287. DOI: https://doi.org/10.1016/j.mcn.2011.06.
013, PMID: 21762782
Leterrier C, Laine´ J, Darmon M, Boudin H, Rossier J, Lenkei Z. 2006. Constitutive activation drives compartment-
selective endocytosis and axonal targeting of type 1 cannabinoid receptors. Journal of Neuroscience 26:3141–
3153. DOI: https://doi.org/10.1523/JNEUROSCI.5437-05.2006, PMID: 16554465
Leterrier C, Clerc N, Rueda-Boroni F, Montersino A, Dargent B, Castets F. 2017. Ankyrin G membrane partners
drive the establishment and maintenance of the axon initial segment. Frontiers in Cellular Neuroscience 11:6.
DOI: https://doi.org/10.3389/fncel.2017.00006, PMID: 28184187
Li P, Merrill SA, Jorgensen EM, Shen K, , , . 2016. Two clathrin adaptor protein complexes instruct Axon-Dendrite
polarity. Neuron 90:564–580. DOI: https://doi.org/10.1016/j.neuron.2016.04.020, PMID: 27151641
Lu HC, Mackie K. 2016. An introduction to the endogenous cannabinoid system. Biological Psychiatry 79:516–
525. DOI: https://doi.org/10.1016/j.biopsych.2015.07.028, PMID: 26698193
Mackie K. 2008. Signaling via CNS cannabinoid receptors. Molecular and Cellular Endocrinology 286:S60–S65.
DOI: https://doi.org/10.1016/j.mce.2008.01.022, PMID: 18336996
Martin S, Henley JM. 2004. Activity-dependent endocytic sorting of kainate receptors to recycling or
degradation pathways. The EMBO Journal 23:4749–4759. DOI: https://doi.org/10.1038/sj.emboj.7600483,
PMID: 15549132
Mascia F, Klotz L, Lerch J, Ahmed MH, Zhang Y, Enz R. 2017. CRIP1a inhibits endocytosis of G-protein coupled
receptors activated by endocannabinoids and glutamate by a common molecular mechanism. Journal of
Neurochemistry 141:577–591. DOI: https://doi.org/10.1111/jnc.14021, PMID: 28295323
McDonald NA, Henstridge CM, Connolly CN, Irving AJ. 2007a. An essential role for constitutive endocytosis, but
not activity, in the axonal targeting of the CB1 cannabinoid receptor. Molecular Pharmacology 71:976–984.
DOI: https://doi.org/10.1124/mol.106.029348, PMID: 17182888
McDonald NA, Henstridge CM, Connolly CN, Irving AJ. 2007b. Generation and functional characterization of
fluorescent, N-terminally tagged CB1 receptor chimeras for live-cell imaging. Molecular and Cellular
Neuroscience 35:237–248. DOI: https://doi.org/10.1016/j.mcn.2007.02.016, PMID: 17467290
Mikasova L, Groc L, Choquet D, Manzoni OJ. 2008. Altered surface trafficking of presynaptic cannabinoid type 1
receptor in and out synaptic terminals parallels receptor desensitization. PNAS 105:18596–18601. DOI: https://
doi.org/10.1073/pnas.0805959105, PMID: 19015531
Fletcher-Jones et al. eLife 2019;8:e44252. DOI: https://doi.org/10.7554/eLife.44252 25 of 26
Research article Neuroscience
Murakami M, Kouyama T. 2008. Crystal structure of squid rhodopsin. Nature 453:363–367. DOI: https://doi.org/
10.1038/nature06925, PMID: 18480818
Niehaus JL, Liu Y, Wallis KT, Egertova´ M, Bhartur SG, Mukhopadhyay S, Shi S, He H, Selley DE, Howlett AC,
Elphick MR, Lewis DL. 2007. CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor
interacting protein CRIP 1a. Molecular Pharmacology 72:1557–1566. DOI: https://doi.org/10.1124/mol.107.
039263, PMID: 17895407
Nordstro¨m R, Andersson H. 2006. Amino-terminal processing of the human cannabinoid receptor 1. Journal of
Receptors and Signal Transduction 26:259–267. DOI: https://doi.org/10.1080/10799890600758252, PMID: 16
818376
Nyı´ri G, Csere´p C, Szabadits E, Mackie K, Freund TF. 2005. CB1 cannabinoid receptors are enriched in the
perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136:811–
822. DOI: https://doi.org/10.1016/j.neuroscience.2005.01.026, PMID: 16344153
Oddi S, Dainese E, Sandiford S, Fezza F, Lanuti M, Chiurchiu` V, Totaro A, Catanzaro G, Barcaroli D, De Laurenzi
V, Centonze D, Mukhopadhyay S, Selent J, Howlett AC, Maccarrone M. 2012. Effects of palmitoylation of cys
(415) in helix 8 of the CB(1) cannabinoid receptor on membrane localization and signalling. British Journal of
Pharmacology 165:2635–2651. DOI: https://doi.org/10.1111/j.1476-5381.2011.01658.x, PMID: 21895628
Oddi S, Totaro A, Scipioni L, Dufrusine B, Stepniewski TM, Selent J, Maccarrone M, Dainese E. 2018. Role of
palmitoylation of cysteine 415 in functional coupling CB1 receptor to Gai2 protein. Biotechnology and Applied
Biochemistry 65:16–20. DOI: https://doi.org/10.1002/bab.1575, PMID: 28722168
Piserchio A, Zelesky V, Yu J, Taylor L, Polgar P, Mierke DF. 2005. Bradykinin B2 receptor signaling: structural and
functional characterization of the C-terminus. Biopolymers 80:367–373. DOI: https://doi.org/10.1002/bip.
20220, PMID: 15682437
Reddy DS. 2017. The utility of cannabidiol in the treatment of refractory epilepsy. Clinical Pharmacology &
Therapeutics 101:182–184. DOI: https://doi.org/10.1002/cpt.441, PMID: 27506704
Robin LM, Oliveira da Cruz JF, Langlais VC, Martin-Fernandez M, Metna-Laurent M, Busquets-Garcia A,
Bellocchio L, Soria-Gomez E, Papouin T, Varilh M, Sherwood MW, Belluomo I, Balcells G, Matias I, Bosier B,
Drago F, Van Eeckhaut A, Smolders I, Georges F, Araque A, et al. 2018. Astroglial CB1 receptors determine
synaptic D-Serine availability to enable recognition memory. Neuron 98:935–944. DOI: https://doi.org/10.1016/
j.neuron.2018.04.034, PMID: 29779943
Rozenfeld R. 2011. Type I cannabinoid receptor trafficking: all roads lead to lysosome. Traffic 12:12–18.
DOI: https://doi.org/10.1111/j.1600-0854.2010.01130.x, PMID: 21040297
Rozenfeld R, Devi LA. 2008. Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. The
FASEB Journal 22:2311–2322. DOI: https://doi.org/10.1096/fj.07-102731, PMID: 18267983
Simon AC, Loverdo C, Gaffuri AL, Urbanski M, Ladarre D, Carrel D, Rivals I, Leterrier C, Benichou O, Dournaud P,
Szabo B, Voituriez R, Lenkei Z. 2013. Activation-dependent plasticity of polarized GPCR distribution on the
neuronal surface. Journal of Molecular Cell Biology 5:250–265. DOI: https://doi.org/10.1093/jmcb/mjt014,
PMID: 23585691
Soltesz I, Alger BE, Kano M, Lee SH, Lovinger DM, Ohno-Shosaku T, Watanabe M. 2015. Weeding out bad
waves: towards selective cannabinoid circuit control in epilepsy. Nature Reviews Neuroscience 16:264–277.
DOI: https://doi.org/10.1038/nrn3937, PMID: 25891509
Stadel R, Ahn KH, Kendall DA. 2011. The cannabinoid type-1 receptor carboxyl-terminus, more than just a tail.
Journal of Neurochemistry 117:1–18. DOI: https://doi.org/10.1111/j.1471-4159.2011.07186.x, PMID: 21244428
Fletcher-Jones et al. eLife 2019;8:e44252. DOI: https://doi.org/10.7554/eLife.44252 26 of 26
Research article Neuroscience
